Donor

A Historic Gift To Accelerate Innovation

"An investment in a bright future for North Carolinians and beyond."

"An investment in a bright future for North Carolinians and beyond."

When Fred Eshelman ’72 made a $100 million commitment to the UNC Eshelman School of Pharmacy in 2014, it was — and still is — the largest gift from an individual in the University’s history. It was an investment in the revolution of new ideas in pharmacy education, practice and science. It was an investment in a bright future for North Carolinians and beyond. The gift created the Eshelman Institute for Innovation.

Read the complete Carolina Story from UNC Eshelman School of Pharmacy…Opens in new window

This is story number 85 in the Carolina Stories 225th Anniversary Edition magazine.

UNC Eshelman School of Pharmacy Funding Priorities

    Explore More Stories

    A group shot of Owen Fenton and his team in the Fenton Lab
    Faculty Support

    Attracting Expertise

    Owen Fenton sees coming to Carolina as a win for his research interests.

    Tim Willson stands with arms crossed with lab equipment in the background.
    Faculty Support

    Bringing the dark proteome into the light

    A Q&A with Tim Willson, the inaugural Harold Kohn Distinguished Professor in Open Science Drug Discovery

    A UNC Eshelman School of Pharmacy student takes notes during class.
    Health

    Strengthening Diversity, Improving Care

    Grants to the UNC Eshelman School of Pharmacy will support diversity and rural care programs.

    Nate Hathaway in the CRISPR Screening Facility
    Research

    UNC-Chapel Hill Awarded Funding for Study of Malan Syndrome

    UNC Eshelman School of Pharmacy and CRISPR Screening Facility collaborate on Malan Syndrome study.

    Health

    Smarter Organ Transplants

    The UNC Eshelman Institute for Innovation's Venture Studio invested in technology for smarter organ transplants.

    Shawn Hingtgen and Jillian Perry
    Research

    Treating the Untreatable

    New research funded by a NIH grant seeks to combat one of the most treatment-resistant cancers